Related Experiment Video
Updated: Jun 13, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
[Repotrectinib in advanced cancers with NTRK fusion after progression or not on a first TRK inhibitor]
Léo Ventelou1, Stéphane Vignot2
1Centre Jean-Perrin, 58, rue Montalemberg, 63011 Clermont-Ferrand cedex, France.
No abstract available in PubMed .
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...